Congress caps insulin at $35—and funds it for the uninsured too

What it does

This bill caps insulin cost-sharing at $35 per 30-day supply (or 25% of negotiated price, whichever is lower) for people with private health insurance starting in 2027, and creates a federal reimbursement program to cover the gap between full price and $35 for uninsured individuals. Insured patients and uninsured people who cannot afford insulin benefit; insurers and pharmacy benefit managers face pressure to absorb or negotiate lower prices.

Why we flagged it

The bill's core mechanism is a dual-track price control: capping cost-sharing for insured patients and subsidizing uninsured patients to reach a $35 threshold. It is straightforward healthcare cost regulation, not a hidden carve-out or rider.

What the text implies

• The $35 cap applies only to 'selected insulin products' chosen by each plan, not all insulins—plans retain discretion to limit coverage breadth, potentially steering patients toward cheaper formulations.
• Pharmacy benefit managers (PBMs) are explicitly named as entities whose price concessions count toward the negotiated price calculation, suggesting the bill anticipates PBM rebate structures will be affected.
• The federal reimbursement program for uninsured individuals creates a new entitlement-like liability with no explicit appropriation cap or sunset, potentially growing as uninsured rates or insulin prices rise.
• Out-of-network insulin delivery is explicitly exempted from the $35 cap, creating a loophole for patients in areas with limited in-network pharmacy access.
• The bill's 'sense of Congress' language requesting future offsets suggests awareness that costs are unbudgeted and may trigger fiscal pressure for cuts elsewhere.

Who it affects

Ordinary people with diabetes gain direct relief: insured patients see capped out-of-pocket costs, and uninsured individuals receive federal subsidies to reach the $35 cap. The primary cost falls on insurers and pharmaceutical supply chains, not on the general public or other patient populations.

Who stands to gain

• diabetes patients (insured and uninsured)
• community health centers and pharmacies (via federal reimbursement)
• potentially generic/biosimilar insulin manufacturers (if price pressure shifts market share)

Named in the bill

HHS (Department of Health and Human Services), DOL (Department of Labor), Treasury, PBMs (pharmacy benefit managers), Private health insurers, Insulin manufacturers, Pharmacies and health care providers, NOW (mapped stock ticker—likely a diabetes-care or insulin-related entity)

Where it stands

• May 13, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• May 13, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.